In this article, Fran DeGrazio identifies six aspects of biologics-based therapy packaging and delivery that, if addressed, may help to ensure successful product development and lifecycle management. They include 1) chemical compatibility with device functionality, 2) long-acting formulations, 3) product stability, 4) primary packaging and device integration, 5) cold storage, and 6) higher concentrations and viscosities.
- 3 Emerging Trends In Drug Delivery Device Pipelines
- Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables
- Closing The Adherence Gap: The Connected Health Era
- Delivery Strategy For Next-Gen Cardiac Gene Therapies
- The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology
- Injecting Cancer Killers: Intratumoral Therapy For Solid Tumors
- The Advantages Of Antibodies Over Ligands In The Alpha Emitter Era
- GenAI: The Muscle Behind Strong Regulatory Intelligence For Combination Products
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Keys To Driving Consistent Quality In Contract Manufacturing
Complex products and supply chains present plenty of opportunities for failure, especially when new products are being developed and launched. This article discusses key ingredients to robust and advanced quality planning that are essential to quality in contract manufacturing.
-
3D Printing Of Pharmaceutical Dosage Forms – Has The Time Come?
Additive manufacturing, or 3D printing, is arguably balancing on the cusp of translation from academic research into industry practice for pharmaceuticals. What will the future impact of 3D printing be?
-
An Elegant Solution For Delivery Of Acid Sensitive Pharmaceuticals
Sustained release drug delivery products offer effective therapies in the treatment of serious chronic diseases, and their development requires customized solutions with tunable material properties.
-
Four Special Fill/Finish Considerations For Vaccine Production
Examine considerations regarding the handling and process for fill/finish to ensure the stability and purity of your vaccine as well as limit unnecessary waste and cost.
-
PHI And Medical Devices: What Device Manufacturers Need To Know
Connected medical devices must treat Protected Health Information (PHI) protection as integral to patient safety and compliance. Understand the data flows and HIPAA requirements to design security.
-
Improve Solubility And Spray Drying Throughput For Brick Dust Compounds
This paper presents three approaches to address poor solubility in organic solvents for spray drying as well as case studies outlining their successful application during development.
-
Driving Sustainability In Spray Drying Through Enabling Technologies
By transitioning to alternative solvents or leveraging process aids, the challenges associated with the use of these chemicals can be addressed, helping create a sustainable, greener footprint.
-
Why Connect An Auto-Injector To A Smartphone?
Why would a person with diabetes want to link their auto-injector to the Internet? Given that smartphones are so central to our everyday lives, it could be argued that the better question is: Why not?
-
Factors To Consider When Selecting A CDMO For Complex Injectables Development And Manufacture
The right CDMO partner will have specialized technologies for complex injectable development along with the equipment, facilities and operations to adopt GMP practices with a "laboratory setting."
-
Increasing Bioavailability With Amorphous Solid Dosage Formulations
Discover the challenges associated with pH-dependent solubility for oral tyrosine kinase inhibitor drugs and how leveraging ASD formulation can help create more effective, patient-friendly drug products.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
DELIVERED BY DEGRAZIO
-
6 Packaging And Delivery Challenges For Biologic Therapies
In this article, Fran DeGrazio identifies six aspects of biologics-based therapy packaging and delivery that, if addressed, may help to ensure successful product development and lifecycle management. They include 1) chemical compatibility with device functionality, 2) long-acting formulations, 3) product stability, 4) primary packaging and device integration, 5) cold storage, and 6) higher concentrations and viscosities.

